ofloxacin has been researched along with Gastritis in 11 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Gastritis: Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.
Excerpt | Relevance | Reference |
---|---|---|
" Two groups exhibited similar adverse event rates (AEA 14." | 3.11 | Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China. ( He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP, 2022) |
" dosing of levofloxacin (81%[95% CI: 78%-89%]vs 84%[95% CI: 66%-97%])." | 2.43 | Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. ( Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P, 2006) |
"Acute phlegmonous gastritis is an uncommon disease, often fatal condition characterized by suppurative bacterial infection of the gastric wall." | 1.37 | [A case of acute phlegmonous gastritis causing gastroparesis and cured with medical treatment alone]. ( Kim, JS; Kim, NY; Lee, KJ; Park, JS; Yun, HK, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (9.09) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 5 (45.45) | 29.6817 |
2010's | 3 (27.27) | 24.3611 |
2020's | 1 (9.09) | 2.80 |
Authors | Studies |
---|---|
He, XJ | 1 |
Zeng, XP | 1 |
Jiang, CS | 1 |
Liu, G | 1 |
Li, DZ | 1 |
Wang, W | 1 |
Ishigami, T | 1 |
Fujikawa, H | 1 |
Miyagawa, M | 1 |
Arakawa, Y | 1 |
Abe, H | 1 |
Ryuzaki, H | 1 |
Matsuoka, S | 1 |
Moriyama, M | 1 |
Li, Y | 1 |
Huang, X | 1 |
Yao, L | 1 |
Shi, R | 1 |
Zhang, G | 1 |
Zhang, J | 1 |
Ye, LP | 1 |
Li, W | 1 |
Shen, LY | 1 |
Kim, NY | 1 |
Park, JS | 1 |
Lee, KJ | 1 |
Yun, HK | 1 |
Kim, JS | 1 |
Saad, RJ | 1 |
Schoenfeld, P | 1 |
Kim, HM | 1 |
Chey, WD | 1 |
Vakil, N | 1 |
Nista, EC | 1 |
Candelli, M | 1 |
Zocco, MA | 1 |
Cremonini, F | 1 |
Ojetti, V | 1 |
Finizio, R | 1 |
Spada, C | 1 |
Cammarota, G | 1 |
Gasbarrini, G | 1 |
Gasbarrini, A | 1 |
Zullo, A | 1 |
Hassan, C | 1 |
Lorenzetti, R | 1 |
Morini, S | 1 |
Zelenková, J | 1 |
Toman, R | 1 |
Bielaszewská, M | 1 |
Hanika, J | 1 |
Zeman, V | 1 |
Glupczynski, Y | 1 |
Labbe, M | 1 |
Burette, A | 1 |
Delmee, M | 1 |
Avesani, V | 1 |
Bruck, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
Intervention | participants (Number) |
---|---|
Esomeprazole+Amox+Levo | 36 |
Esomeprazole+Bismuth+Tetra+Levo | 49 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
Intervention | participants (Number) |
---|---|
Esomeprazole+Amox+Levo+Tetra | 13 |
Esomeprazole+Amox+Levo | 21 |
2 reviews available for ofloxacin and Gastritis
Article | Year |
---|---|
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Re | 2010 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
3 trials available for ofloxacin and Gastritis
Article | Year |
---|---|
Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; China; Drug Therapy, Combination; Esomepraz | 2022 |
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; E | 2006 |
Treatment failure of ofloxacin in Campylobacter pylori infection.
Topics: Anti-Bacterial Agents; Campylobacter; Campylobacter Infections; Clinical Trials as Topic; Double-Bli | 1987 |
6 other studies available for ofloxacin and Gastritis
Article | Year |
---|---|
[A case of phlegmonous gastritis which resolved with medical treatment].
Topics: Aged; Anti-Bacterial Agents; Cellulitis; Drug Therapy, Combination; Female; Gastritis; Humans; Levof | 2008 |
Iatrogenic gastric wall abscess infected with Enterobacter cloacae after biopsy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Diagnosis, Differential; Drug Therapy, Comb | 2010 |
[A case of acute phlegmonous gastritis causing gastroparesis and cured with medical treatment alone].
Topics: Acinetobacter; Acute Disease; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Ceftri | 2011 |
Helicobacter pylori treatment: a practical approach.
Topics: Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; | 2006 |
Helicobacter pylori eradication: do we have another ace up our sleeve?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Infective Agents; Be | 2001 |
[Campylobacter pylori and treatment of duodenal ulcer].
Topics: Adult; Campylobacter; Campylobacter Infections; Duodenal Ulcer; Female; Gastritis; Humans; Male; Mid | 1990 |